Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus

Core Insights - Gilead Sciences, Inc. is recognized as one of the 13 Best NASDAQ Dividend Stocks to buy currently [1] - Barclays initiated coverage with an Equal Weight rating and set a price target of $155, indicating that the stock's current valuation is considered "rich" [2] Financial Outlook - Gilead's financial outlook for 2026 is conservative, projecting sales of $800 million for Yeztugo, lower than analyst expectations of $907 million [3] - Yeztugo generated $96 million in sales in Q4, surpassing Wall Street estimates of $88 million [3] - The CEO noted a reduction in the 2026 sales growth outlook by about 2 percentage points due to pricing agreements and insurance coverage uncertainties [4] Business Performance - The HIV business showed steady growth, with sales increasing by 6% in 2025, and a similar increase is expected in 2026 [5] - Gilead anticipates adjusted earnings per share between $8.45 and $8.85 for 2026, slightly above the average analyst projection of $8.75 [5] Company Focus - Gilead focuses on developing treatments for serious diseases, including HIV, viral hepatitis, cancer, COVID-19, and inflammatory conditions, with infectious disease treatment being a core aspect of its business [6]